Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging
Open Access
- 4 October 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 3 (1), srep02859
- https://doi.org/10.1038/srep02859
Abstract
Drug transit through the blood-brain barrier (BBB) is essential for therapeutic responses in malignant glioma. Conventional methods for assessment of BBB penetrance require synthesis of isotopically labeled drug derivatives. Here, we report a new methodology using matrix assisted laser desorption ionization mass spectrometry imaging (MALDI MSI) to visualize drug penetration in brain tissue without molecular labeling. In studies summarized here, we first validate heme as a simple and robust MALDI MSI marker for the lumen of blood vessels in the brain. We go on to provide three examples of how MALDI MSI can provide chemical and biological insights into BBB penetrance and metabolism of small molecule signal transduction inhibitors in the brain – insights that would be difficult or impossible to extract by use of radiolabeled compounds.This publication has 37 references indexed in Scilit:
- High-Sensitivity MALDI-MRM-MS Imaging of Moxifloxacin Distribution in Tuberculosis-Infected Rabbit Lungs and Granulomatous LesionsAnalytical Chemistry, 2011
- Transformative effects of higher magnetic field in Fourier transform ion cyclotron resonance mass spectrometryJournal of the American Society for Mass Spectrometry, 2010
- PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541Neuro-Oncology, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Assessment of the blood–brain barrier in CNS drug discoveryNeurobiology of Disease, 2010
- Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and DevelopmentThe AAPS Journal, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathwaysPurinergic Signalling, 2008
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasJCI Insight, 2008
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005